TIDMANCR
RNS Number : 5220X
Animalcare Group PLC
30 April 2019
30 April 2019
Animalcare Group plc
("Animalcare", the "Company" or the "Group")
Full Year Results for the 12 months ended 31 December 2018
Animalcare Group plc (AIM: ANCR), the European Animal Health
business, announces its full year results for the year ended 31
December 2018.
Financial Highlights
-- Reported revenue growth of 16.3% to GBP72.5m (2017: GBP62.3m)
o Up 2.7% on a proforma basis
-- Underlying* EBITDA increased by 21.7% to GBP11.8m (2017: GBP9.7m)
o Up 2.8% on a proforma basis
-- Statutory loss before tax, which incorporates non-underlying
items, decreased to GBP0.4m (2017: GBP0.4m profit) with reported
basic loss per share decreased to 1.7p (2017: 0.2p earnings per
share)
-- Improved underlying* cash conversion to 79.9% (2017: 65.9%)
with net debt reduced by GBP2.3m to GBP23.6m
-- Proposed final dividend of 2.4 pence per share giving a total
dividend of 4.4 pence per share for 2018
Operational Highlights (including post-period)
-- Jenny Winter, formerly of AstraZeneca, appointed Chief Executive Officer in October 2018
-- Leadership team strengthened by appointment of Group
Functional leaders in Supply Chain, Commercial, New Product
Opportunities (CSO) and Technical / Regulatory functions and HR. In
addition, we have appointed new country managers in Spain, the UK
and Belgium
-- Portfolio prioritisation performed including the sale of the
non-core Wholesale business in Q3 2018, in line with focus on the
higher-margin veterinary pharmaceuticals business
-- Ten new products launched in 2018 with an additional six
submissions made for products that are scheduled for launch in 2019
or early 2020
-- Strategy was focussed to reflect the new combined Animalcare
group and was approved by the Board post period. It builds on the
experience and success of the legacy companies and reflects the
rapidly growing and changing marketplace. The Board believe the
five strategic priorities below will drive the future success of
Animalcare and will contribute to both the short and long-term
sustainable growth.
o Build strong financial basis through revenue growth, cash
conversion, EPS growth and EBITDA margin growth
o Grow the business through a focussed portfolio of existing
products and build a robust future pipeline in five key therapy
areas in the companion animal and equine markets
o Build on existing customer relationships with vets and other
stakeholders to deliver trusted products and services
o Business development focus with partners to in license and
acquire innovative products
o Organisation for success, building leadership strength and
attract, retain and develop talent for the future
*underlying measures are before the effect of non-underlying
items which excludes fair value adjustments on acquired inventory,
amortisation of acquired intangibles and acquisition and
integration costs. A reconciliation to statutory measures is
provided in the Chief Financial Officer's Review.
Jan Boone, Chairman of Animalcare Group plc, commenting on the
results said: "Animalcare made good progress in 2018 as we focus on
creating a competitive platform for future growth in the global
animal health sector. We continue to improve the underlying
profitability of the Group, and the disposal of our Wholesale
Division was in line with our strategy to focus on the
higher-margin veterinary pharmaceuticals business, a key growth
driver. In order to maximise our potential as a significant player
in the European and international animal health sector, we
appointed Jenny Winter as CEO in October 2018 to maximise the
potential of the business. With Jenny's leadership and expertise, I
look forward to delivering our financial goals and strategic
objectives over the coming years."
Jenny Winter, CEO of Animalcare Group plc, said: "Since joining
Animalcare in October last year, I have been impressed by the
competitive strengths of the business and the size of the growth
opportunity. I have conducted a detailed review of all areas of the
business and set out a strategy to enable us to build upon our
capabilities. Our goal is to deliver sustainable and profitable
growth and to achieve this, we will focus on meeting the needs of
vets in therapeutic areas where we have existing strengths and can
further add value. Improving cash generation is a key focus for the
business and we will continue to drive improvements in supply chain
efficiency and closely monitor our cost base, whilst selectively
investing in future innovation. Achieving this will build an
effective and focused organisation that is fit for the future and
deliver growth over the next three to five years. "
Analyst briefing today
Jenny Winter, Chief Executive Officer, and Chris Brewster, Chief
Financial Officer, will host a meeting and conference call for
analysts to provide an update the Company, followed by a Q&A
session, at 09:00am BST today at the offices of Panmure Gordon
& Co, One New Change, London, EC4M 9AF.
Dial-in details:
International and UK dial-in:
+44 (0) 2071 928000
Belgium dial-in:
080048740
Conference ID:
5769312
Presentation slides will be made available on Animalcare's
website, www.animalcaregroup.co.uk, prior to the conference
call.
For further information, please contact:
Animalcare Group plc Tel: 01904 487 687
Jenny Winter, Chief Executive
Officer
Chris Brewster, Chief Financial
Officer
Panmure Gordon (Nominated Adviser Tel: 020 7886 2500
& Broker)
Corporate Finance
Freddy Crossley / Emma Earl
Corporate Broking
James Stearns
Consilium Strategic Communications
Tel: 020 3709 5709
Amber Fennell/Jonathan Birt/Angela
Gray /Olivia Manser
Animalcare@consilium-comms.com
About Animalcare (www.Animalcaregroup.co.uk)
Animalcare Group plc is a UK AIM listed veterinary sales and
marketing organisation resulting from the merger of Animalcare and
Ecuphar NV in July 2017. Animalcare operates in 32 countries in
Europe and a further 16 worldwide. The company is focused on
bringing new and innovative products to market through its own
development pipeline, partnerships and via acquisition.
CHAIRMAN'S STATEMENT
Animalcare continued to make steady progress in 2018 as we focus
on creating a competitive platform for future growth in the
international animal health sector. Group revenues from continuing
operations were up 16.3% to GBP72.5m from GBP62.3m with underlying
EBITDA increasing by 21.7% to GBP11.8m (2017: GBP9.7m). On a
proforma basis, which is used by the Board for comparison of
financial performance, as set out in the unaudited income statement
in the Chief Financial Officer's Review, revenue and underlying
EBITDA growth versus 2017 was 2.7% and 2.8% respectively. After
underlying adjustments totalling GBP9.4m, the loss before tax for
the year on a reported basis was GBP0.4m (2017: GBP0.4m
profit).
Sales growth was affected towards the end of the year by supply
challenges related to third-party manufacturers, some of which
impacted the wider market. We also experienced some delays to new
product launches and lower demand in the large animal portfolio,
particularly for antibiotics which was reflective of an overall
market decline in demand.
Strategically, we decided to dispose of the Wholesale Division
in order to focus resources on the higher-margin veterinary
pharmaceuticals business. We also continued to focus on
integration, supply chain efficiency and optimising portfolios and
product launches across our expanded network.
The Board is confident of the long-term prospects of the animal
health market and is actively preparing the business to make the
most of the opportunities. Our key competitive advantages include a
significant presence across Europe, with products sold in 32
markets directly and through partners. We also benefit from
specialisation in key therapeutic areas for the companion animal
and equine markets and believe we can capitalise on a growing
reputation as a chosen partner for non-European companies and
researchers wanting to commercialise innovative products in
Europe.
In order to maximise the potential of the business, the Board
appointed Jenny Winter as CEO in October 2018. Jenny has an
excellent track record in the pharmaceutical industry, most
recently with AstraZeneca, with particular expertise in supply
chain effectiveness, which we believe is fundamental to improving
our overall performance. We are grateful to Chris Cardon for his
contribution as CEO and for taking on the role of Chief Strategy
Officer.
Jenny has initiated a full review and identified a clear path
for Animalcare as a business focused around core therapy areas and
higher margin products with the vet as our primary customer. We are
also setting out financial goals, including growing faster than the
markets in which we operate and improving cash generation to enable
us to invest in future growth and innovation.
Further details of the new strategy are set out in the Chief
Executive Officer's Review and are linked to our Key Performance
Indicators.
I would like to thank our employees for their support and
dedication during 2018. We look forward to 2019 and beyond with
confidence. We believe Animalcare is excellently placed to leverage
its geographic, structural and therapeutic strengths, and has the
opportunity to become a significant and recognised brand across
Europe, with global potential for innovative products through
best-in-class partnerships.
We look forward to keeping you updated on our progress during
the year.
Jan Boone
Non-Executive Chairman
CHIEF EXECUTIVE OFFICER'S REVIEW
Since joining Animalcare in October 2018, I have been impressed
by the competitive strengths of the business and the quality of the
growth opportunity. Since joining and following the disposal of our
wholesale business in September 2018, a thorough review has been
undertaken. Following this review and detailed discussions with the
Board, I have set out a strategy to enable us to build on the
existing portfolio, experience and capabilities to become an
important player in the European animal health market and beyond. I
have also reviewed our pipeline and established the principles we
will use to build a sustainable future.
The strategy is built around five pillars:
-- Strong finances
-- Growth portfolio
-- Customer relationships
-- Focused business development
-- The organisation for success
In the seven European markets where we have commercial
operations we market and sell our own products. We also market and
sell products from other companies through our established sales
teams. In countries where we do not have sales teams, we work with
our network partners to commercialise our own products. With this
footprint we are active in 32 countries in Europe and a further 16
in the rest of the world.
We employ over 110 fully trained sales representative and
technical experts who are working closely with our customers
including dedicated Key Account Managers who work with our larger
Corporate Partners
We have a broad portfolio of licensed drugs, vaccines and care
products including nutraceuticals in the companion animal, equine
and production animal segments of the market. In the UK we are also
one of the leading providers of pet microchips and have a
successful pet reunification service.
2018 Operational performance:
Financials
On a proforma basis, sales in 2018 increased by 2.7% to GBP72.5m
versus the prior year and were in line with the market growth for
the countries and segments in which we operate. This increase is
driven by organic growth in companion animals (+6.0%) offset by a
decline in production animal sales of 3.6%.
Growth in Companion Animals was driven by the launch of new
products including Cosequin (Spain) and the annualised impact of
products launched in 2017. Equine sales were flat and the decline
in sales in production animals is driven by the reduction in the
use of antibiotics and our antibiotics sales versus 2017 declined
at 15%. Belgium and Italy saw the largest decline.
Our top three selling products in 2018 were Dinalgen Injection
for the treatment of pain, Conofite, an antifungal treatment and
Orozyme, an established oro-dental product and accounted for 12% of
sales.
The top 20 products accounted for 47% of our total sales.
Filavac (+38%), Aqupharm fluids (+27%) and Cosequin (joint
supplement) (+230%) were the most significant growth drivers in the
portfolio. Our microchip business in the UK continued to perform
well with growth of 31%. Whilst overall sales in farm animal
declined, Dinalgen Injection performed strongly with revenue up
31%.
Our operating overheads increased by +0.7% with a mix of
increases in employee costs and decreases in other operational
expenses.
Underlying EBITDA increased by 2.8% driven by growth in Germany
and the UK, offset by a decline in Belgium and Spain. Overall
growth was impacted by some out of stocks due to supply chain
challenges, some delays in approvals for new products and the pace
of the decline in antibiotic prescribing.
New product launches and regulatory filings.
We have been building our product portfolio and technical
efficiencies in 2018. We have made 17 submissions for products that
are either new to our portfolio, or new in a specific country both
within Europe and Globally. We have made over 50 submissions
including extensions to the life cycle of existing products that
will increase efficiency and decrease costs.
We launched ten new products in 2018 and will see the full year
impact of these launches in 2019.
In 2018 we completed a strategic review of our development
pipeline and re focused our activities to drive growth in the next
five years.
We have accelerated the development programme for our novel pain
treatment by four months and we terminated the development of two
products, either due to commercial or technical reasons.
Six projects were submitted to the regulatory authorities in
2018 including extensions to our "Care" range across multiple
countries that will strengthen our portfolio in the key therapeutic
areas. Launches are planned for these products throughout 2019 and
into early 2020.
People
We have continued the work that was done in 2017 to strengthen
our Leadership Team and have established a core team to drive
simplicity and avoid duplication. We have appointed Martin Gore as
our Group Head of Commercial, to drive excellence within our Sales
and Marketing teams. Stephen Pearson has been appointed Group Head
of Supply Chain and will be focussed on improving customer service
and on time in full delivery to our customers as well as managing
inventory. Karolyn Tapper continues to lead our Technical team and
Christiaan Cardon has taken the role of Chief Strategy Officer with
responsibility for identifying new opportunities for the Group.
The newly created Leadership Team consists of the Group
functions and Country Managers to ensure that we remain close to
our customers through the leaders in each country. Post year end,
we have further strengthened our Country Manager team with the
appointment of Sara Maddens to lead the team in Benelux.
Having the right people in place is critical to our long-term
success. I am determined that Animalcare will develop a positive
and unified culture, with a rewards system and career development
path to attract and retain the best talent in our industry. We plan
to introduce a Long-Term Incentive Plan in May 2019 to reward
senior employees for sustained performance.
Integration
Animalcare has not yet seen the benefit of the combined
organisation in the financial returns however great progress has
been made on the 5 key areas outlined in plan in the past six
months. Our highest priorities are:
1. Drive maximum value from the combined portfolio.
2. Establish a robust supply chain.
3. Align our pipeline to the growth strategy
4. Align our people strategy including our reward system.
5. Drive commercial excellence
We have established a new Leadership Team and organisational
structure to facilitate the implementation of the integration plan
and to drive performance including through simplification, focus
and cross functional working. Clear targets are in place to track
our progress.
Our growth strategy
To deliver sustainable and profitable growth we will focus on
therapeutic areas where we have existing capabilities and with the
greatest growth potential, through higher margin innovation,
expansion of our geographic reach and careful control of our costs.
By growing faster than the markets where we operate, controlling
OPEX and improving operating cash conversion, we can focus
resources where they will bring the best returns while continuing
to reward shareholders.
Our future Pipeline
Our pipeline will focus on five therapeutic areas in the
companion animal and equine markets where we are already strong and
have the potential to add value through innovation. These are pain
management, dermatology, dental, disease prevention and surgery.
Animalcare also owns identichip, the UK's leading pet microchipping
business and database, with significant scope for growth in the UK
and internationally.
We will continue to support our production animal business
through targeted products with specific customer groups.
Our customers
We will focus on vets and veterinary groups as our main
customers, benefiting from our existing expertise and strong
relationships. We want to become the chosen partner in Europe for
innovative animal health products for companies around the world.
We will seek to improve the quality and profitability of our
portfolio by in-licensing and acquiring late- and commercial-stage
products, and accelerating our own R&D through targeted
investment.
Our footprint
We have established networks in 25 countries in Europe and
another 16 globally. We will continue to develop these networks to
maximise the sales of our products and where it makes sense to
establish a presence we will do so - either as a stand-alone
business or in partnership.
Summary and outlook
We are building an effective and focussed organisation that is
fit for the future and we have a clear strategy to grow over the
next 3 to 5 years. One of the critical things for our organisation
is to track progress and we have established goals, objectives and
measures so we can ensure we achieve our financial targets. We have
established clear milestones and will report against those. To
deliver on the expectations we set,we will focus on generating cash
for investing, for rewarding our shareholders and for paying our
debt. Success will be driven by the 5 pillars of our strategy -
Strong finances, a portfolio for growth, our customer
relationships, our business development and most importantly - our
organisation of highly engaged and talented people.
I look forward to sharing more details over the coming weeks,
months and years as we implement our strategy for success.
Jenny Winter
Chief Executive Officer
CHIEF FINANCIAL OFFICER'S REVIEW
Introduction and presentation of results
On 13th July 2017, Animalcare Group plc completed the reverse
acquisition of Ecuphar NV. 2018 therefore reflects the first full
year of trading as a combined Group. On a statutory basis, and in
accordance with IFRS3, the results for the comparative year ended
31st December 2017 represent twelve months of Ecuphar NV and
approximately five and a half months of Animalcare Group plc as
previously constituted.
In addition, following the divestment of our Wholesale business
on 4th September 2018, both the 2018 and 2017 financial information
have been presented to show the Pharmaceuticals segment as
continuing operations separately from the Wholesale segment, which
has been classified as discontinued.
Accordingly, to help Shareholders to assess the Group, an
unaudited Proforma Consolidated Income Statement has been provided,
which reflects twelve months of trading from the continuing
Pharmaceuticals segment for both entities for 2018 and 2017. The
Board believes that this statement provides the most appropriate
basis for comparison of current and future operating performance.
On this basis, the Group has delivered proforma revenue growth of
2.7% to GBP72.5m (2017: GBP70.6m) and proforma underlying EBITDA
growth of 2.8% to GBP11.8m (2017: GBP11.5m). On a statutory basis,
including non-underlying items, the Group delivered a loss after
tax of GBP0.8m (2017: GBP0.2m profit).
Underlying and Statutory Results
To provide comparability across reporting periods, the Group
presents its results on both an underlying and statutory (IFRS)
basis. The Directors believe that presenting our financial results
on an underlying basis, which exclude non - underlying items,
provides a clearer understanding of business performance. IFRS
results include these items to provide the statutory results. All
figures are reported at actual exchange rates (AER) unless
otherwise stated. Commentary will include references to constant
exchange rates (CER) to identify the impact of foreign exchange
movements. A reconciliation between underlying and statutory
results is provided at the end of this financial review.
Financial Review
Pro forma Consolidated Income Statement (unaudited)
Compared to the statutory results for 2018, the unaudited Pro
forma Consolidated Income Statement set out below represents the
continuing pharmaceuticals segment for both 2018 and 2017, with the
2017 comparatives including an additional 28 weeks of Animalcare
Group plc's results prior to the reverse acquisition. This has the
impact of increasing 2017 revenue and underlying EBITDA by GBP8.3m
and GBP1.8m respectively as set out in the table below
:
Unaudited Unaudited
---------------------------------------- ------------------------------- --------------------------------
Continuing Total proforma
Continuing Operations Animalcare Continuing
Operations -Post-acquisition pre-acquisition Operations
2018 2017 2017 2017
GBP'000 GBP'000 GBP'000 GBP'000
---------------------------------------- ----------- ------------------ ---------------- --------------
Revenue 72,470 62,291 8,267 70,558
Gross Profit 37,339 32,325 4,464 36,789
Operating expenses (37,122) (31,309) (5,753) (37,062)
Operating profit/(loss) 217 1,016 (1,289) (273)
Depreciation, amortisation & impairment 9,588 6,480 199 6,679
Non-underlying items 1,993 2,202 2,867 5,069
Underlying EBITDA 11,798 9,698 1,777 11,475
Net financial expenses (574) (639) (1) (640)
Profit/(loss) before tax (357) 377 (1,290) (913)
Taxation 135 (292) (82) (374)
Net (loss)/profit (222) 85 (1,372) (1,287)
Underlying net profit 7,016 5,175 1,309 6,484
Underlying basic EPS (p) 11.7p - - 10.8p
---------------------------------------- ----------- ------------------ ---------------- --------------
Revenue
On a proforma basis, the Group delivered revenue growth of 2.7%
to GBP72.5m (2017: GBP70.6m), split by product category as shown in
the table below:
Unaudited Unaudited
------------------- --------- --------- --------
% Change
2018 2017 at AER
GBP'000 GBP'000 %
------------------- --------- --------- --------
Companion Animals 44,465 41,937 6.0%
Production Animals 22,824 23,680 (3.6%)
Equine and other 5,181 4,941 1.4%
------------------- --------- --------- --------
Total 72,470 70,558 2.7%
------------------- --------- --------- --------
Companion Animals revenue continues to be the largest proportion
of the Group's business, representing 61.4% of total sales, up from
59.4%. As our existing portfolio continues to mature and be
impacted by pricing pressure and changes in the competitor
landscape, new products remain the main driver for the overall
revenue growth of 6.0% to GBP44.5m (2017: GBP41.9m). We launched
seven new products during the year including the nutritional
supplement Cosequin in Spain, which contributed GBP2.4m sales in
total. This was supplemented by GBP0.8m annualised growth of
products launched in 2017 that were sourced from our partners,
principally in Germany. Overall growth was impacted by supply
challenges towards the year end relating to certain third-party
manufacturers.
Production Animals revenue contracted by 3.6% versus prior year
period largely driven by lower demand for antibiotics offset in
part by higher export sales of in particular Dinalgen
(anti-inflammatory). Equine and other sales were broadly flat at
GBP5.2m.
Underlying proforma continuing EBITDA increased by 2.8% to
GBP11.8m with corresponding margin consistent with prior year at
16.3%. Gross margins at 51.5% modestly declined compared to prior
year (2017: 52.1%) primarily reflecting lower margin sales mix in
Companion Animals and the competitive environment. SG&A costs
as a percentage of revenue reduced in the year from 35.9% to 35.2%
as the business has continued to focus on costs efficiencies whilst
investing in our people to support the integration and future
growth.
Underlying proforma continuing basic EPS increased by 8.3% for
the year to 11.7p, based on a weighted average number of shares of
60.0m applied to both 2018 and 2017. The effective tax rate was
22.3% (2017: 23.0%) primarily reflecting increased research and
developments tax credits and partial utilisation of tax losses.
Underlying and Statutory Results
As a result of the reverse acquisition of Ecuphar NV, both the
underlying and statutory basis for reporting results for the year
ended 31st December 2017 include approximately five and a half
months of Animalcare Group plc as previously constituted. The 2018
results are those noted in the unaudited Proforma Consolidated
Income Statement above.
Overview of Underlying financial results - Continuing
Operations
% Change
2018 2017 at AER
GBP'000 GBP'000 %
---------------------------- -------- -------- --------
Revenue 72,470 62,291 16.3%
Gross Profit 37,339 32,325 15.5%
Gross Margin % 51.5% 51.9% (0.4%)
Underlying Operating Profit 9,604 7,560 27.8%
Underlying EBITDA 11,798 9,698 21.7%
Underlying EBITDA margin % 16.34% 15.6% 0.8%
Basic Underlying EPS (p) 11.7p 12.3p (4.9%)
---------------------------- -------- -------- --------
We delivered revenue of GBP72.5m and underlying EBITDA of
GBP11.8m, representing growth of 16.3% and 21.7% respectively
compared to the previous year. This was achieved through a
combination of modest underlying growth as noted in the proforma
results review together with a full year trading impact of the
acquired Animalcare operations.
Underlying EBITDA margin improved to 16.3% largely reflecting
the higher margin Animalcare business together with overall focus
on costs to improve operating leverage. This focus includes a
restructuring of our UK commercial team to put more emphasis on
supporting larger corporate customers as well as continuing to
provide strong service levels to independent practices. We expect
this trend to continue and will closely monitor and adapt the
Group's operations accordingly.
Basic underlying EPS decreased to 11.7 pence reflecting the
35.6% increase in underlying profit after tax to GBP7.0m offset by
the significant increase in the weighted average number of shares
resulting from the full year impact of the reverse acquisition (see
note 8).
Overview of reported financial results
Including the loss from the discontinued operations and
non-underlying items, the Group reported a loss after tax of
GBP1.0m (2017: GBP0.2m profit).
A reconciliation of underlying results to reported results for
the year to 31st December 2018 is shown in the table below:
Acquisition,
restructuring, 2017
2018 Amortisation integration 2018 Reported
Underlying Discontinued and impairment and other Reported results
results operations of intangibles costs results (restated)
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------------------------- ----------- ------------ --------------- --------------- --------- -----------
Revenue 72,470 - - - 72,470 62,291
Gross Profit 37,339 - - - 37,339 31,924
Selling, general & administrative
expenses (24,312) - (4,789) - (29,101) (26,396)
Research & development expenses (3,466) - (1,296) - (4,762) (2,799)
Net other operating income
(expenses) 43 - (1,309) (1,993) (3,259) (1,713)
Operating Profit 9,604 - (7,394) (1,993) 217 1,016
Net finance expenses (574) - - - (574) (639)
Profit/(loss) before tax 9,032 - (7,394) (1,993) (357) 377
Taxation (2,016) - 1,822 329 135 (292)
Profit/(loss) after tax 7,016 - (5,573) (1,664) (222) 85
Loss/(profit) from discontinued
operations - (776) - - (776) 99
Profit/(loss) for the year 7,016 (776) (5,573) (1,664) (998) 184
Basic EPS (p) 11.7p (1.7p) 0.2p
--------------------------------- ----------- ------------ --------------- --------------- --------- -----------
The sale of our wholesale division was completed on 4th
September 2018 with financial effect from 1st July 2018. The loss
from discontinued operations was GBP0.8m which primarily represents
the loss on disposal. Additional details are shown in note 4. Of
the total GBP3.0m consideration, GBP2.4m has been received with a
further GBP0.4m payable to the Group on 30th June 2019 in relation
to the remaining intercompany balance owed. The balance of
approximately GBP0.2m is subject to achieving specific revenue
targets between 1st July 2019 and 30th June 2020 and payable in
July 2020.
The amortisation and impairment of intangibles charge of GBP7.4m
(pre-tax) principally comprises GBP4.6m charge arising on the
acquired intangibles relating to the reverse acquisition and
GBP2.5m charge in respect of previous acquisitions made by Ecuphar
NV, namely Esteve SA which was acquired on 30th April 2015.
The remaining statutory items totalling GBP2.0m largely relate
to restructuring and integration costs as detailed in note 5.
Restructuring costs of GBP1.2m principally relate to executive
changes, senior management restructuring and the UK commercial team
reorganisation as noted earlier.
The reported basic loss per share, which incorporates
non-underlying items, decreased to 1.7 pence (2017: 0.2 pence
earnings per share).
Dividends
The Board is proposing a final dividend of 2.4 pence per share,
adding to the interim dividend of 2.0 pence per share paid in
November 2018, giving a total dividend of 4.4 pence per share for
the year ended 31st December 2018, the first full financial year as
a combined Group. The Board continues to monitor the dividend
policy, recognising the need for a balance between investment to
support future growth and dividend flow to deliver overall value to
our shareholders.
Cash flow, net debt and borrowing facilities
The Group is committed to improving cash generation, important
to generate the funds we need to invest for growth and to maintain
dividend payments. We will monitor progress using cash conversion
as a percentage of underlying EBITDA as set out in the table
below:
2018 2017
GBP'000 GBP'000
----------------------------------------- -------- --------
Underlying EBITDA 11,798 9,698
Net cash flow from operations 7,430 2,425
Non-underlying items 1,993 3,968
Underlying net cash flow from operations 9,423 6,393
Cash conversion % 79.9% 65.9%
----------------------------------------- -------- --------
The Group's underlying cash conversion significantly improved
during the year to 79.9%, with net cash flow generated by our
operations increasing to GBP7.4m (2017: GBP2.4m). Working capital
increased by GBP0.9m, largely relating to further increased stocks.
Our Group Head of Supply Chain has a clear target to reduce
inventory levels over the next two years. Cash taxes of GBP2.2m
were significantly higher than 2017 largely due to settlement of
prior year taxes in Belgium and higher cash tax in Spain.
GBP'000
------------------------------------------------- --------
Net debt at 1st January 2018 (25,908)
Net cash generated from operations 7,430
Net capital expenditure (4,781)
Proceeds from divestment of wholesale operations 2,403
Net finance expenses (626)
Dividends paid (2,401)
Receipts from issue of share capital 170
Other cash movements 474
Foreign exchange on cash and borrowings (349)
------------------------------------------------- --------
Net debt at 31st December 2018 (23,588)
------------------------------------------------- --------
Net capital expenditure of GBP4.8m largely comprises investment
in our product development pipeline of GBP4.2m from which six new
products are expected to be launched during 2019 and into early
2020. The balance of expenditure largely relates to investment in
our IT infrastructure which has made strong progress. This includes
a new CRM system in Italy and SAP in the UK which went live on 1st
January 2019. Both represent important steps in delivering our
objective of common platforms across the Group which will help to
drive integration and improve efficiencies.
The net borrowing position at the end of the year was GBP23.6m,
representing net debt to underlying EBITDA leverage of 2.0 times
(maximum bank covenant ratio is 3.5 times). At 31st December 2018,
total facilities were GBP46.4m, of which GBP29.8m, net of cash
balances, was utilised, leaving headroom of GBP16.6m. These bank
facilities, together with the Group's operational cash flow,
indicate that the Group has sufficient facilities available to fund
its operations and allow for future investment.
Brexit
Whilst the outcome of the Brexit negotiations remain unclear our
contingency preparations are on track to maintain commercial
supply. We expect to incur one-off costs of circa GBP0.3m in
relation to transfer of product registrations during 2019.
Summary and outlook
The Group delivered continued revenue growth in the year and
translation through to both underlying profit and cash conversion
is beginning to improve. We remain focused on our medium to
long-term objective of delivering sustainable profit growth and
improved cash generation, with cash flow expected to be supported
by lower inventories.
Strategically and operationally it continues to be a time of
change for the Group with the pace of integration of our businesses
accelerating given the greater focus by our Leadership Team. During
2019, the drive for improved efficiency and integration across the
business will continue including the integration of our Product
Development and Regulatory teams. We will also focus on portfolio
optimisation, improving service and driving efficiencies in our
supply chain, all of which will require investment.
Whilst our performance was not as strong as originally expected,
we have made steady progress across the business over the last 12
months and delivered growth at a time of much change within our
business and the market. We will continue to seek opportunities to
grow our business and I believe we are well placed to deliver
medium to long-term shareholder value.
Chris Brewster
Chief Financial Officer
CONSOLIDATED INCOME STATEMENT
YEARED 31ST DECEMBER 2018
For the year ended 31 December
Non-Underlying
(note 4)
Underlying (Restated) Total
Non-Underlying
Underlying (note 4) Total 2017 2017 2017
GBP'000 Notes 2018 2018 2018 (Restated) (Restated) (Restated)
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Revenue 5 72,470 - 72,470 62,291 - 62,291
Cost of sales (35,131) - (35,131) (29,966) (401) (30,367)
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Gross profit 37,339 - 37,339 32,325 (401) 31,924
Research and development
expenses (3,466) (1,296) (4,762) (2,048) (751) (2,799)
Selling and marketing
expenses (12,435) - (12,435) (12,592) - (12,592)
General and administrative
expenses (11,877) (4,789) (16,666) (10,214) (3,591) (13,805)
Net other operating
income / (expenses) 43 (3,302) 3,259) 89 (1,801) (1,713)
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Operating profit/(loss) 9,604 (9,387) 217 7,560 (6,544) 1,016
Financial expenses 6 (840) - (840) (735) - (735)
Financial income 7 266 - 266 96 - 96
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Profit/(loss) before
tax 9,032 (9,387) (357) 6,922 (6,544) 377
Income tax 8 (2,016) 2,151 135 (1,746) 1,454 (292)
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Net profit from continuing
operations 7,016 (7,236) (222) 5,176 (5,090) 85
Net profit/(loss)
from
discontinuing operations 3 40 (816) (776) 109 (10) 99
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Net profit/(loss) 7,056 (8,052) (998) 5,285 (5,100) 184
Net profit/(loss)
attributable to:
The owners of the
parent 7,058 (8,052) (996) 5,285 (5,100) 184
Non-controlling interest (2) - (2) - - -
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Earnings per share
for profit/(loss)
from continuing operations
attributable to the
ordinary equity holders
of the company:
Basic earnings per
share 9 11.7p (0.4p) 12.3p 0.2p
Diluted earnings per
share 9 11.7p (0.4p) 12.3p 0.2p
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
Earnings per share
for profit/(loss)
attributable to the
ordinary equity holders
of the company:
Basic earnings per
share 9 11.8p (1.7p) 12.6p 0.4p
Diluted earnings per
share 9 11.8p (1.7p) 12.5p 0.4p
---------------------------- ----- ---------- -------------- -------- ----------- -------------- -----------
In order to aid understanding of underlying business
performance, the Directors have presented underlying results before
the effect of exceptional and other items. These exceptional and
other items are analysed in detail in note 4 to this financial
information. The accompanying notes form an integral part of these
consolidated financial information.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
YEARED 31ST DECEMBER 2018
GBP'000 2018 2017
---------------------------------------------------------- ----- ----
Net (loss)/profit for the year (998) 184
---------------------------------------------------------- ----- ----
Other comprehensive income
---------------------------------------------------------- ----- ----
Cumulative translation differences* 165 664
---------------------------------------------------------- ----- ----
Other comprehensive income, net of tax 165 664
---------------------------------------------------------- ----- ----
Total comprehensive (expense)/income for the year, net of
tax (833) 848
---------------------------------------------------------- ----- ----
Total comprehensive (expense)/income attributable to:
The owners of the parent (831) 848
Non-controlling interest (2) -
---------------------------------------------------------- ----- ----
* May be reclassified subsequently to profit & loss
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
YEARED 31ST DECEMBER 2018
For the year ended
31 December
------------------------------------------------ ----- --------------------
GBP'000 Notes 2018 2017
------------------------------------------------ ----- --------- ---------
Assets
------------------------------------------------ ----- --------- ---------
Non-current assets
Goodwill 10 50,937 51,413
Intangible assets 11 51,334 54,037
Property, plant & equipment 477 825
Deferred tax assets 8 1,699 1,603
Other financial assets 59 72
Other non-current assets 294 -
------------------------------------------------ ----- --------- ---------
Total non-current assets 104,800 107,950
------------------------------------------------ ----- --------- ---------
Current assets
Inventories 14,891 16,795
Trade receivables 13,084 16,680
Available-for-sale financial assets - 464
Other current assets 2,736 1,934
Cash and cash equivalents 8,035 7,579
------------------------------------------------ ----- --------- ---------
Total current assets 38,746 43,452
------------------------------------------------ ----- --------- ---------
Total assets 143,546 151,402
------------------------------------------------ ----- --------- ---------
Liabilities
------------------------------------------------ ----- --------- ---------
Current liabilities
Borrowings 12 (648) (633)
Trade payables (11,907) (14,128)
Tax payables (1,016) (1,520)
Accrued charges & deferred income 13 (2,325) (2,116)
Other current liabilities (3,864) (3,201)
------------------------------------------------ ----- --------- ---------
Total current liabilities (19,760) (21,598)
------------------------------------------------ ----- --------- ---------
Non-current liabilities
Borrowings 12 (30,975) (32,854)
Deferred tax liabilities 8 (5,521) (6,454)
Deferred income 13 (617) (780)
Provisions (81) (72)
------------------------------------------------ ----- --------- ---------
Total non-current liabilities (37,194) (40,160)
------------------------------------------------ ----- --------- ---------
Total Liabilities (56,954) (61,758)
------------------------------------------------ ----- --------- ---------
Net Assets 86,592 89,644
------------------------------------------------ ----- --------- ---------
Equity
Share capital 14 12,012 11,983
Share premium 132,729 132,588
Reverse acquisition reserve (56,762) (56,762)
Accumulated losses (4,732) (1,347)
Other reserves 3,345 3,180
Equity attributable to the owners of the parent 86,592 89,642
Non-controlling interest 14 - 2
Total equity 86,592 89,644
------------------------------------------------ ----- --------- ---------
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
YEARED 31ST DECEMBER 2018
Attributable to the owners of the
parents
------------------- -------------------------------------------------------
Reverse Non-
Share Share Treasury Accumulated acquisition Other controlling Total
GBP'000 capital premium shares losses reserve reserve Total interest equity
------------------- -------- -------- -------- ----------- ------------ -------- ------- ------------ -------
At 1 January,
2018 11,983 132,588 - (1,347) (56,762) 3,180 89,642 2 89,644
------------------- -------- -------- -------- ----------- ------------ -------- ------- ------------ -------
Net loss - - - (996) - - (996) (2) (998)
Other comprehensive
income - - - - - 165 165 - 165
Total comprehensive
expense - - - (996) - 165 (831) (2) (833)
------------------- -------- -------- -------- ----------- ------------ -------- ------- ------------ -------
Dividends paid - - - (2,401) - - (2,401) - (2,401)
Exercise of
share options 29 141 - - - - 170 - 170
Share based
payments - - - 12 - - 12 - 12
------------------- -------- -------- -------- ----------- ------------ -------- ------- ------------ -------
At 31 December,
2018 12,012 132,729 - (4,732) (56,762) 3,345 86,592 - 86,592
------------------- -------- -------- -------- ----------- ------------ -------- ------- ------------ -------
Retained Reverse Non-
Share Share Treasury earnings/Accumulated acquisition Other controlling Total
GBP'000 capital premium shares losses reserve reserve Total interest equity
-------------- ------- ------- -------- -------------------- ----------- ------- -------- ----------- --------
At 1 January,
2017 4,244 6,687 - 1,258 5,146 2,518 19,853 2 19,855
-------------- ------- ------- -------- -------------------- ----------- ------- -------- ----------- --------
Net profit - - - 184 - - 184 - 184
Other
comprehensive
income - - - - - 662 662 - 662
Total
comprehensive
income - - - 184 - 662 846 - 846
-------------- ------- ------- -------- -------------------- ----------- ------- -------- ----------- --------
Dividends paid - - - (2,816) - - (2,816) - (2,816)
Shares issued
as
consideration 5,750 94,880 - - - - 100,630 - 100,630
Exercise of
share options 275 3,953 - - - - 4,228 - 4,228
Share issue
cost - (1,218) - - - - (1,218) - (1,218)
Arising on
reverse
acquisition - - - - (61,908) - (61,908) - (61,908)
Issue of new
shares 1,714 28,286 - - - - 30,000 - 30,000
Cash - - - - - - - - -
consideration
for Ecuphar
Share based
payments - - - 27 - - 27 - 27
At 31
December,
2017 11,983 132,588 - (1,347) (56,762) 3,180 89,642 2 89,644
-------------- ------- ------- -------- -------------------- ----------- ------- -------- ----------- --------
Reverse acquisition reserve
Reverse acquisition reserve represents the reserve that has been
created upon the reverse acquisition of Animalcare Group plc.
Other reserve
Other reserve mainly relates to currency translation
differences. These exchange differences arise on the translation of
subsidiaries with a functional currency other than Sterling.
CONSOLIDATED CASH FLOW STATEMENT
YEARED 31ST DECEMBER 2018
GBP'000 Notes 2018 2017
------------------------------------------------------- ----- ------- --------
Operating activities
Loss/profit before tax from continuing operations (357) 377
Loss/profit before tax from discontinued operations 3 (776) 167
Loss/Profit before tax (1,133) 544
Non-cash and operational adjustments
Depreciation of property, plant & equipment 333 327
Amortization of intangible assets 11 7,965 6,053
Impairment of intangible assets 11 852 -
Impairment of goodwill 10 456 -
Share-based payment expense 12 27
Loss/(gain) on disposal of property, plant & equipment (2) 2
Loss on disposal of subsidiary 3 682 -
Movement allowance for bad debt and inventories 620 652
Financial income (254) (91)
Financial expense 879 747
Impact of foreign currencies 16 25
Other 2 (30)
------------------------------------------------------- ----- ------- --------
Movements in working capital
Increase in trade receivables (540) (2,079)
Increase in inventories (1,207) (1,359)
Increase /(decrease) in payables 904 (2,115)
Income tax paid (2,155) (278)
------------------------------------------------------- ----- ------- --------
Net cash flow from operating activities 7,430 2,425
------------------------------------------------------- ----- ------- --------
Investing activities
Purchase of property, plant & equipment (213) (184)
Purchase of intangible assets 11 (4,568) (2,379)
Proceeds from the sale of property, plant & equipment
(net) 6 31
Payments to acquire subsidiaries 3 - (33,145)
Cash and cash equivalents acquired under reverse
acquisition 3 - 6,293
Proceeds from sale of subsidiary 3 2,403 -
Sale/(purchase) of available for sale financial
investments 459 (45)
------------------------------------------------------- ----- ------- --------
Net cash flow used in investing activities (1,913) (29,429)
------------------------------------------------------- ----- ------- --------
For the
year ended
31 December
GBP'000 Notes 2018 2017
------------------------------------------------------- ----- ------------ --------
Financing activities
Proceeds from loans and borrowings and convertible
debt - 8,298
Repayment of loans and borrowings (2,257) (649)
Receipts from issue of share capital 170 29,402
Dividends paid (2,401) (2,816)
Interest paid (637) (528)
Other financial expense 11 (129)
Net cash flow (used in)/from financing activities (5,114) 33,578
------------------------------------------------------- ----- ------------ --------
Net increase of cash and cash equivalents 403 6,574
Cash and cash equivalents at beginning of year 7,579 951
Exchange rate differences on cash and cash equivalents 53 54
------------------------------------------------------- ----- ------------ --------
Cash and cash equivalents at end of year 8,035 7,579
------------------------------------------------------- ----- ------------ --------
For the year ended
31 December
----------------------
GBP'000 Notes 2018 2017
------------------------------------------------------- ----- ------------ --------
Reconciliation of net cash flow to movement in net
debt
Net increase in cash and cash equivalents in the
year 403 6,574
Cash flow from decrease/(increase) in debt financing 2,257 (7,649)
Foreign exchange differences on cash and borrowings (349) (1,051)
Movement in net debt in the year 2,311 (2,126)
Net debt at the start of the year (25,908) (23,782)
Debt transferred on sale of subsidiary 3 9 -
Net debt at the end of the year (23,588) (25,908)
------------------------------------------------------- ----- ------------ --------
1. Financial information
The financial information set out above does not constitute the
Company's statutory accounts for the year ended 31st December 2018
but is derived from the 2018 accounts. The statutory accounts of
Animalcare Group plc for the year ended 31st December 2017 have
been delivered to the Registrar of Companies and those for 2018
will be delivered in due course. The external auditor has reported
on those accounts; the report was (i) unqualified, (ii) did not
include references to any matters to which the external auditor
drew attention by way of emphasis without qualifying the reports
and (iii) did not contain statements under section 498(2) or (3) of
the Companies Act 2006.
2. Basis of preparation
The Group financial statements have been prepared and approved
by the Directors under the historical cost convention, except for
the revaluation of certain financial instruments, in accordance
with International Financial Reporting Standards ("IFRS") as
adopted by the European Union "adopted IFRSs") and the Companies
Act 2006 as applicable to companies reporting under IFRS. They have
also been prepared in accordance with the requirements of the AIM
Rules.
This is the first set of the Group's annual financial statements
in which IFRS 15 Revenue from Contracts with Customers and IFRS 9
Financial Instruments have been applied.
The consolidated financial statements cover the year ended 31st
December 2018 and comprise the consolidated results of the Group.
On 13th July 2017 the Group completed the reverse acquisition of
Ecuphar NV ("Ecuphar"). In the comparatives financial statements,
for the year ending 31st December 2017, the results of the group
are included as of the 13th of July 2017. For the period from 1st
January 2017 to the date of the reverse acquisition the results of
Ecuphar, the substance of the reverse acquisition, are solely
shown.
Wholesale divestment 2018
Following the divestment of the Wholesaling business Medini NV
registered in Belgium, Legeweg 157i, 8020 Oostkamp on 4th September
2018, 2017 financial information have been restated in accordance
with IFRS 5, to show continuing operations separately from
discontinued operations. Both continuing and discontinued
operations were restated to include elements relating to
transactions between entities which were previously eliminated in
the consolidation as intra-group.
Reverse acquisition Animalcare Group Plc 2017
The accounting policy adopted by the Directors applies the
principles of IFRS 3 (Revised) 'Business Combinations' in
identifying the accounting parent as Ecuphar NV and the
presentation of the Group consolidated statements of the Company
(the legal parent) as a continuation of financial statements of the
accounting parent or legal subsidiary (Ecuphar NV).
This policy reflects the commercial substance of this
transaction as follows:
-- The original shareholders of the legal subsidiary undertaking
were the most significant shareholders following admission to AIM,
owning 46.9% of the issued share capital;
-- The assets and liabilities of the legal subsidiary Ecuphar NV
are recognised and measured in the Group financial statements at
the pre-combination carrying amounts without restatement to fair
value;
-- The retained earnings and other equity balances recognised in
the Group financial statements reflect the retained earnings and
other equity balances of Ecuphar NV immediately before the business
combination;
-- The results of the period from 1st January 2017 to the date
of the business combination are those of Ecuphar NV;
-- The equity structure appearing in the Group financial
statements reflects the equity structure of the legal parent,
including the equity instruments issued under the share for share
exchange to effect the business combination and adjusted in
accordance with IFRS 3. This results in the creation of a 'reverse
acquisition reserve' as at 1st January 2017, being the difference
between the Company equity structure and that of Ecuphar NV.
3. Business Combinations and disposals of subsidiaries
Business combinations
Reverse acquisition of Animalcare Group plc
On 13th July 2017 Animalcare Group plc acquired 100% of the
share capital of Ecuphar NV for a total consideration of
GBP133,775k, satisfied through a combination of a share-for-share
exchange and GBP33,145k in cash net of commissions.
The acquisition of Ecuphar NV by Animalcare Group plc is deemed
to be a reverse acquisition under the provisions of IFRS 3
"Business Combinations".
In accounting for a reverse acquisition (rather than an
acquisition) the combined financial statements are deemed to be a
continuation of the books of the legal acquiree (Ecuphar NV) rather
than a continuation of those of the legal acquirer (Animalcare
Group plc).
The assets and liabilities of the Ecuphar NV are recognised and
measured in the Group financial statements at the pre-combination
carrying amounts, without restatement to fair value and no goodwill
arises in relation to them.
Conversely, the assets of Animalcare Group plc and Animalcare
Ltd are consolidated at their fair values.
The overall effect is that the consolidated financial statements
are prepared from an Ecuphar NV perspective rather than Animalcare
Group plc, and in summary this means:
The comparative consolidated financial information is that of
Ecuphar NV rather than that of Animalcare Group plc;
The result for the year and consolidated cumulative profit and
loss reserves are those of the Ecuphar NV plus the post-acquisition
results of the Animalcare Group plc;
A reverse acquisition reserve of GBP (56,762)k has been
created;
The share capital and share premium account are that of
Animalcare Group plc; and
The cost of the combination has been determined from the
perspective of Ecuphar NV.
Goodwill arises on the reverse acquisition when comparing the
deemed fair value consideration of Animalcare Group plc acquiring
the shares of Ecuphar NV. The fair value of the consideration is
the market capitalisation of Animalcare Group plc at the
acquisition date based on the closing share price on 12th July of
355p per share.
Reverse Acquisition Animalcare Group Plc
Carrying
value at Fair value Fair value
acquisition adjust- at acquisi-
GBP'000 date ments tion date
---------------------------------------- ------------ ---------- ------------
Assets
Historical goodwill 12,711 (12,711) -
Intangible assets 4,658 30,957 35,615
Tangible assets 227 - 227
Deferred tax asset 149 885 1,034
Inventory 2,014 401 2,415
Trade receivables 3,392 - 3,392
Other current assets 559 - 559
Cash 6,293 - 6,293
---------------------------------------- ------------ ---------- ------------
30,003 19,532 49,535
---------------------------------------- ------------ ---------- ------------
Liabilities
Deferred tax liabilities (414) (6,843) (7,257)
Trade payables (3,948) - (3,948)
Other liabilities (4,040) - (4,040)
(8,402) (6,843) (15,245)
---------------------------------------- ------------ ---------- ------------
Total identified assets and liabilities 21,601 12,689 34,290
---------------------------------------- ------------ ---------- ------------
Goodwill 41,048
Fair value of consideration - - 75,338
---------------------------------------- ------------ ---------- ------------
The acquisition consideration, net assets and goodwill are based
upon the reverse acquisition of Animalcare Group plc by Ecuphar NV.
The fair value of the consideration is the market capitalisation of
Animalcare Group plc at the closing share price of 355p per share
on 12th July 2017. Transaction costs of equity transactions
relating to the issue and readmission of the Company's shares are
accounted for as a deduction from equity where they relate to the
issue of new shares.
The fair value of the net assets acquired and shown in the table
above was GBP34,290k. The fair value of the consideration was
GBP75,338k resulting in goodwill on reverse acquisition of
GBP41,048k. In addition, the fair value uplift of inventory
amounted to GBP401k, the fair value uplift of the identified
intangibles amounted to GBP30,957k. Deferred tax assets and
liabilities respectively were increased by GBP885k and
GBP(6,843)k.
Disposal of subsidiaries
On 4th September 2018, the Group announced and completed the
disposal of its Wholesaling business Medini NV registered in
Belgium, Legeweg 157i, 8020 Oostkamp.
The Group recognised a loss including expenses in relation to
the disposal of GBP682k during the year ending 31st December 2018.
This is based on the total consideration of GBP2,989k and a net
asset value of GBP3,622k, excluding intercompany debt.
The Group has received an initial cash consideration of
GBP2,413k including intercompany loan balances due from the
Wholesale Division to other Animalcare Group Plc companies. A
further GBP362k is payable to on 30th June 2019 in relation to the
remaining intercompany balance owed. The balance of approximately
GBP214k is subject to achieving specific revenue targets between
1st July 2019 and 30th June 2020 and payable in July 2020.
In accordance with IFRS 5, the income statement for the twelve
months ended 31 December 2017 and 2018 have been restated to show
continuing operations separately from discontinued operations. Both
continuing and discontinued operations were restated to include
elements relating to transactions between entities which were
previously eliminated in the consolidation as intra-group. The
effect of including these elements is shown as consolidation
adjustments.
Total continuing
Continuing Discontinued Consolidation and discontinued
operations operations adjustments operations
GBP'000 2018 2018 2018 2018
------------------------------------ ----------- ------------ ------------- -----------------
Revenue 72,470 16,572 (719) 88,323
Cost of sales (35,131) (15,059) 689 (49,501)
Gross profit 37,339 1,513 (30) 38,822
------------------------------------ ----------- ------------ ------------- -----------------
Research and development expenses (4,762) - - (4,762)
Selling and marketing expenses (12,435) (1,111) 46 (13,500)
General and administrative expenses (16,666) (387) (18) (17,071)
Net other operating expenses (3,259) (762) 2 (4,019)
Operating profit/(loss) 217 (746) - (529)
------------------------------------ ----------- ------------ ------------- -----------------
Financial expenses (840) (39) 20 (859)
Financial income 266 9 (20) 255
Loss before tax (357) (776) - (1,133)
------------------------------------ ----------- ------------ ------------- -----------------
Income tax 135 - - 135
Net loss (222) (776) - (998)
------------------------------------ ----------- ------------ ------------- -----------------
Continuing Discontinue Consolidation As reported
operations operations adjustments last year
GBP'000 2017 2017 2017 2017
------------------------------------ ----------- ----------- ------------- -----------
Revenue 62,291 23,938 (2,553) 83,676
Cost of sales (30,367) (21,523) 2,477 (49,413)
Gross profit 31,924 2,415 (76) 34,263
------------------------------------ ----------- ----------- ------------- -----------
Research and development expenses (2,799) - - (2,799)
Selling and marketing expenses (12,592) (1,594) 88 (14,098)
General and administrative expenses (13,805) (625) 26 (14,404)
Net other operating expenses (1,713) (12) (38) (1,762)
Operating profit 1,016 184 - 1,200
------------------------------------ ----------- ----------- ------------- -----------
Financial expenses (735) (30) 18 (747)
Financial income 96 13 (18) 91
Profit before tax 377 167 - 544
------------------------------------ ----------- ----------- ------------- -----------
Income tax (292) (68) - (360)
Net profit 85 99 - 184
------------------------------------ ----------- ----------- ------------- -----------
The net cash flow by discontinued operations can be found
below:
For the year ended
31 December
--------------------------------------------------- --------------------
GBP'000 2018 2017
--------------------------------------------------- --------- ---------
Net cash flow from operating activities 133 107
Net cash flow used in investing activities (94) (83)
Net cash flow used in financing activities (28) (30)
--------------------------------------------------- --------- ---------
Net increase/(decrease) of cash & cash equivalents 11 (6)
--------------------------------------------------- --------- ---------
The major classes of assets and liabilities of the Wholesaling
business at the disposal date can be found below:
GBP'000
--------------------------------------------------------------------- -------
Non-current assets
Goodwill 106
Intangible assets 2
Property, plant & equipment 244
--------------------------------------------------------------------- -------
Current assets
Inventories 2,669
Trade receivables 2,451
Other current assets 77
Cash and cash equivalents 10
--------------------------------------------------------------------- -------
Total assets classified as held for sale 5,559
Current liabilities
Borrowings (9)
Trade payables (1,690)
Tax payables (52)
Accrued charges & deferred income (12)
Other current liabilities (169)
--------------------------------------------------------------------- -------
Non-current liabilities
Deferred tax liabilities (5)
--------------------------------------------------------------------- -------
Liabilities associated with assets classified as held for sale (1,937)
Total net assets 3,622
Consideration received or receivable:
Cash 2,413
Receivable 576
--------------------------------------------------------------------- -------
Total disposal consideration 2,989
Carrying amount of net assets sold (3,622)
Loss on sale before reclassification of foreign currency translation
reserve (633)
Reclassification of foreign currency translation reserve (49)
--------------------------------------------------------------------- -------
Loss on sale (682)
Loss attributable to minority (2)
Loss attributable to owners of the parent (680)
Selling price received in cash 2,413
Cash and cash equivalents transferred (10)
--------------------------------------------------------------------- -------
Total cash flow 2,403
--------------------------------------------------------------------- -------
4. Non-Underlying items
For the year ended
31 December
------------------------------------------------------------------ --------------------
GBP'000 2018 2017
------------------------------------------------------------------ --------- ---------
Amortisation and impairment of acquisition related intangibles
Classified within Research and development expenses 1,296 751
Classified within General and administrative expenses 4,789 3,591
Classified within net other operating expenses 513 -
------------------------------------------------------------------ --------- ---------
Total amortisation and impairment of acquisition related
intangibles 6,598 4,342
------------------------------------------------------------------ --------- ---------
Fair value uplift of inventory acquired through reverse
acquisition - 401
Restructuring costs 1,235 -
Acquisition and integration costs 485 1,454
Impairment on goodwill and intangibles 796 -
Other non-underlying items 273 347
------------------------------------------------------------------ --------- ---------
Total non-underlying items before taxes 9,387 6,544
------------------------------------------------------------------ --------- ---------
Tax impact (2,151) (1,454)
------------------------------------------------------------------ --------- ---------
Total non-underlying items after taxes from continuing operations 7,236 5,090
------------------------------------------------------------------ --------- ---------
Other non-underlying items from discontinued operations 134 10
Loss on disposal 682 -
------------------------------------------------------------------ --------- ---------
Total non-underlying items after taxes 8,052 5,100
------------------------------------------------------------------ --------- ---------
The amortisation charge of acquisition-related intangibles
largely relates to the Esteve acquisition of GBP2,037k (2017:
GBP2,017k) and the reverse acquisition of Animalcare Group plc of
GBP3,676k (2017: GBP1,685k, which was the amortization impact from
the acquisition date, 12th of July 2017, until the 31st of December
2017).
Restructuring costs of GBP1,235 k include GBP203k in relation to
compensation for loss of office in respect of Iain Menneer and a
further GBP382k for other senior management.
5. Segment information - from continuing operations
For management purposes, the Group was organised into 2
segments: the Pharmaceuticals and the Wholesale segments. From 2018
onwards, the Group will only report one segment, being
Pharmaceuticals, due to the sale of its Wholesaling business.
The Pharmaceutical segment is active in the development and
marketing of innovative pharmaceutical products that provide
significant benefits to animal health.
The Wholesale segment focused on the sale of veterinary
pharmaceuticals, supplies and instruments in the Belgian market and
is presented under discontinued operations in the financial
information.
The measurement principles used by the Group in preparing this
segment reporting are also the basis for segment performance
assessment. The Board of Directors of the Group acts as the Chief
Operating Decision Maker. As a performance indicator, the Chief
Operating Decision Maker controls performance by the Group's
revenue, gross margin, Underlying EBITDA and EBITDA. EBITDA is
defined by the Group as net profit plus finance expenses, less
financial income, plus income taxes and deferred taxes, plus
depreciation, amortisation and impairment. Underlying EBITDA equals
EBITDA plus non-underlying items.
The following table summarises the segment reporting from
continuing operations for each of the reportable periods. As
management's controlling instrument is mainly revenue-based, the
reporting information does not include assets and liabilities by
segment and is as such not presented per segment.
Adjustments
GBP'000 Pharma Wholesale Total segments and eliminations Consolidated
------------------------------------ ------ --------- -------------- ----------------- ------------
For the year ended 31 December 2018
Revenues 72,470 - 72,470 - 72,470
Gross Margin 37,339 - 37,339 - 37,339
Gross Margin % 52% 52% 52%
Segment underlying EBITDA 11,798 - 11,798 - 11,798
Segment underlying EBITDA % 16% 16% 16%
Segment EBITDA 9,805 - 9,805 - 9,805
Segment EBITDA % 14% 14% 14%
------------------------------------ ------ --------- -------------- ----------------- ------------
For the year ended 31 December 2017
Revenues 62,291 - 62,291 - 62,291
Gross Margin 31,924 - 31,924 - 31,924
Gross Margin % 51% 51% 51%
Segment underlying EBITDA 9,698 - 9,698 - 9,698
Segment underlying EBITDA % 16% 16% 16%
Segment EBITDA 7,496 - 7,496 - 7,496
Segment EBITDA % 12% 12% 12%
------------------------------------ ------ --------- -------------- ----------------- ------------
The segment EBITDA is reconciled with the consolidated net
profit of the year as follows:
For the year ended
31 December
------------------------------------------ --------------------
GBP'000 2018 2017
------------------------------------------ --------- ---------
Segment EBITDA 9,805 7,496
Depreciation, amortization and impairment (9,588) (6,480)
------------------------------------------ --------- ---------
Operating profit 217 1,016
Financial expenses (840) (735)
Financial income 266 96
Income taxes (869) (592)
Deferred taxes 1,004 300
------------------------------------------ --------- ---------
Net (loss)/profit (222) 85
------------------------------------------ --------- ---------
Non-current assets excluding deferred tax assets and financial
instruments located in Belgium, Spain, Portugal, the United Kingdom
and other geographies are as follows:
For the year ended
31 December
--------------------------------------------------------------- --------------------
GBP'000 2018 2017
--------------------------------------------------------------- --------- ---------
Belgium 18,423 19,691
Spain 2,127 2,170
Portugal 4,122 4,101
UK 73,913 76,010
Other 4,510 4,375
--------------------------------------------------------------- --------- ---------
Non-current assets excluding deferred tax assets and financial
instruments 103,101 106,347
--------------------------------------------------------------- --------- ---------
Revenue by product category
For the year ended
31 December
-------------------------------------- --------------------
GBP'000 2018 2017
-------------------------------------- --------- ---------
Companion animals 44,465 33,670
Production animals 22,824 23,680
Horses 4,618 4,682
Petfood, Instrumentation and Services 563 259
-------------------------------------- --------- ---------
Total 72,470 62,291
-------------------------------------- --------- ---------
Revenue by geographical area:
For the year ended
31 December
----------------------- --------------------
GBP'000 2018 2017
----------------------- --------- ---------
Europe 71,507 61,424
Belgium 8,260 8,781
The Netherlands 1,719 1,142
United Kingdom 16,802 9,459
Germany 9,784 8,907
Spain 20,706 20,909
Italy 4,984 4,458
Portugal 4,600 4,514
European Union - other 4,652 3,254
Asia 558 471
Middle East Africa 139 45
Other 266 351
----------------------- --------- ---------
Total 72,470 62,291
----------------------- --------- ---------
Revenue by category:
For the year ended
31 December
--------------- --------------------
GBP'000 2018 2017
--------------- --------- ---------
Product sales 71,025 62,162
Services sales 1,445 129
--------------- --------- ---------
Total 72,470 62,291
--------------- --------- ---------
Product revenue is recognised when the performance obligation is
satisfied at a point in time. Service revenue is recognised by
reference of the stage of completion.
Share Options:
During the year Iain Menneer exercised 5,142 share options
granted in 2014 under the Save As You Earn scheme (SAYE) at an
option price of GBP1.05 per share. The value of this exercise was
GBP5,399. The SAYE options held by Chris Brewster, totalling
options over 8,571 shares, lapsed during the year. As at 31st
December 2018, no options are held or have been granted to the
Directors.
6 Financial expenses - from continuing operations
Financial expenses includes the following elements:
For the year ended
31 December
------------------------- --------------------
GBP'000 2018 2017
------------------------- --------- ---------
Interest expense 637 527
Foreign currency losses 119 111
Other financial expenses 84 97
Total 840 735
------------------------- --------- ---------
7 Financial income - from continuing operations
Financial income includes the following elements:
For the year ended
31 December
-------------------------------- --------------------
GBP'000 2018 2017
-------------------------------- --------- ---------
Foreign currency exchange gains 192 64
Other financial income 74 32
Total 266 96
-------------------------------- --------- ---------
8 Income tax - from continuing operations
Income tax
The following table shows the breakdown of the tax expense for
2018 and 2017:
For the year ended
31 December
----------------------------------------------------------------- --------------------
GBP'000 2018 2017
----------------------------------------------------------------- ---------- --------
Current tax charge (963) (770)
Tax adjustments in respect of previous years 94 178
Total current tax charge (869) (592)
Deferred tax - origination and reversal of temporary differences 597 300
Deferred tax - adjustments in respect of previous years 407 -
Total deferred tax charge 1,004 300
----------------------------------------------------------------- ---------- --------
Total tax income/(expense) for the year 135 (292)
----------------------------------------------------------------- ---------- --------
The total tax expense can be reconciled to the accounting profit
as follows:
For the year ended
31 December
------------------------------------------------------------ --------------------
GBP'000 2018 2017
------------------------------------------------------------ ------------ ------
(Loss)/profit before tax (357) 377
Tax at 19% (2017: 19.25%) 68 (73)
Effect of:
Overseas tax rates (64) 126
Non-deductible expenses (156) (201)
Income not subject to tax 215 66
Other tax credits and tax deductions - (1)
Other permanent tax differences (133) (56)
Other taxes (38) (37)
Changes in statutory enacted tax rate (15) (294)
Tax adjustments in respect of previous year 501 178
Non recognition of deferred tax on current year losses (195) -
Share based payment deductions (48) -
------------------------------------------------------------ ------------ ------
Income tax credit/(expense) as reported in the consolidated
income statement 135 (292)
------------------------------------------------------------ ------------ ------
The tax credit of GBP2,151k (2017: GBP1,454k) shown within
"non-underlying items" on the face of the consolidated income
statement, which forms part of the overall tax credit of GBP135k
(2017, tax charge of GBP292k) relates to the items in note 5.
The tax rates used for the 2018 and 2017 reconciliation above
are the corporate tax rates of 29.58% in 2018 and 33.99% in 2017
(Belgium), 25% (the Netherlands), 30.7% in 2018 and 29% in 2017
(Germany), 33% (France), 25% (Spain), 24% in (Italy), 21%
(Portugal) and 19% (the United Kingdom). These taxes are payable by
corporate entities in the above mentioned countries on taxable
profits under tax law in that jurisdiction.
Changes to the UK corporation tax rate were substantially
enacted as part of the Finance Bill 2017 (on 6th September 2016).
They include reductions to the main rate to reduce the rate to 17%
from 1st April 2020.
A similar tax reform in Belgium was substantially enacted in
December 2017. The tax rate will gradually decrease from 33.99%
(current) to 29.58% in 2018 and 2019 and to 25% from 2020
onwards.
Deferred taxes at the balance sheet date have been measured
using the enacted tax rates and reflected in these financial
statements.
Deferred tax
(a) Recognised deferred tax assets and liabilities
Assets Liabilities Total
------------------------------------- ------------ ---------------- ----------------
GBP'000 2018 2017 2018 2017 2018 2017
------------------------------------- ----- ----- ------- ------- ------- -------
Goodwill 23 (7) (632) (362) (609) (369)
Intangible assets 834 515 (4,969) (6,118) (4,135) (5,603)
Property, plant and equipment 45 28 (43) (25) 2 3
Financial fixed assets 1 1 - - 1 1
Inventory 3 51 (21) (24) (18) 27
Trade and other payables/receivables 3 297 43 - 46 297
Accruals and deferred income - 19 - 75 - 94
Tax losses carried forward 790 699 101 - 891 699
------------------------------------- ----- ----- ------- ------- ------- -------
Total 1,699 1,603 (5,521) (6,454) (3,822) (4,851)
------------------------------------- ----- ----- ------- ------- ------- -------
(b) Movements during the year
Movement of deferred taxes during 2018:
Balance Acquired
at through Foreign Balance
1 January Recognised Disposal business exchange at 31 December
GBP'000 2018 in income of subsidiaries combinations adjustments 2018
------------------------------ ---------- ---------- ---------------- ------------- ------------ ---------------
Goodwill (369) (234) - - (6) (609)
Intangible assets (5,603) 1,458 - - 10 (4,135)
Property, plant and equipment 3 (1) - - - 2
Financial fixed assets 1 - - - - 1
Inventory 26 (50) 5 - 1 (18)
Trade and other
payables/receivables 298 (250) - - (2) 46
Accruals and deferred income 94 (94) - - - -
Tax losses carry forward
and other tax benefits 699 175 - - 17 891
------------------------------ ---------- ---------- ---------------- ------------- ------------ ---------------
Net deferred tax (4,851) 1,004 5 - 20 (3,822)
------------------------------ ---------- ---------- ---------------- ------------- ------------ ---------------
Movement of deferred taxes during 2017:
Balance Acquired Balance
at through Foreign at
1 January Recognised Disposal business exchange 31 December
GBP'000 2017 in income of subsidiaries combinations adjustments 2017
--------------------------------- ---------- ---------- ---------------- ------------- ------------ ------------
Goodwill (220) (138) - - (11) (369)
Intangible assets 175 565 - (6,356) 13 (5,603)
Property, plant and equipment 13 27 - (38) 1 3
Financial fixed assets 1 - - - - 1
Inventory 46 57 (4) (76) 3 26
Trade and other
payables/receivables 565 (285) - - 18 298
Accruals and deferred income 173 (331) - 247 5 94
Tax losses carry forward and
other tax benefits 292 405 (13) - 15 699
--------------------------------- ---------- ---------- ---------------- ------------- ------------ ------------
Net deferred tax 1,045 300 (17) (6,223) 44 (4,851)
--------------------------------- ---------- ---------- ---------------- ------------- ------------ ------------
Tax losses
The Group has unused tax losses, tax credits and notional
interest deduction available in an amount of GBP3,141k for 2018
(2017: GBP2,636k).
Deferred tax assets have been recognised on available tax losses
carried forward for some legal entities, resulting in amounts
recognised of GBP788k (2017: GBP699k). This was based on
management's estimate that sufficient positive taxable basis will
be generated in the near future for the related legal entities with
fiscal losses.
9. Earnings per share
Diluted earnings per share amounts are calculated by dividing
the net profit attributable to ordinary equity holder of the parent
Company by the weighted average number of ordinary shares
outstanding during the year plus the weighted average number of
ordinary shares that would be issued on conversion of all potential
dilutive ordinary shares.
The following income and share data was used in the earnings per
share computations:
Profit / (loss) from continuing and discontinuing operations
For the year ended 31 December
------------------------------------------------ ----------------------------------------
2018 2017 2018 2017
GBP'000 Underlying Underlying Total Total
------------------------------------------------ ----------- ----------- ------ ------
Net profit/(loss) from continuing operations 7,016 5,175 (222) 85
Net profit/(loss) from discontinuing operations 40 109 (776) 99
------------------------------------------------ ----------- ----------- ------ ------
Net profit/(loss) attributable to ordinary
equity holders of the parent adjusted for
the effect of dilution 7,056 5,284 (998) 184
------------------------------------------------ ----------- ----------- ------ ------
Average number of shares (basic and diluted)
For the year ended 31 December
----------------------------------------------------- ------------------------------------------------
2018 2017 2018 2017
number of shares Underlying Underlying Total Total
----------------------------------------------------- ----------- ----------- ---------- ----------
Weighted average number of ordinary shares for basic
earnings per share 60,008,714 41,998,692 60,008,714 41,998,692
Dilutive potential ordinary shares 5,452 178,191 5,452 178,191
----------------------------------------------------- ----------- ----------- ---------- ----------
Weighted average number of ordinary shares adjusted
for effect of dilution 60,014,166 42,176,883 60,014,166 42,176,883
----------------------------------------------------- ----------- ----------- ---------- ----------
Basic earnings/(loss) per share
For the year ended 31 December
--------------------------------------------------- ----------------------------------------
2018 2017 2018 2017
Underlying Underlying Total Total
Pence Pence Pence Pence
--------------------------------------------------- ----------- ----------- ------ ------
From continuing operations attributable to
the ordinary equity holders
of the company 11.7 12.3 (0.4) 0.2
From discontinued operation 0.1 0.3 (1.3) 0.2
--------------------------------------------------- ----------- ----------- ------ ------
Total basic earnings/(loss) per share attributable
to the ordinary equity holders of the company 11.8 12.6 (1.7) 0.4
--------------------------------------------------- ----------- ----------- ------ ------
Diluted earnings/(loss) per share
For the year ended 31 December
---------------------------------------------------
2018 2017 2018 2017
Underlying Underlying Total Total
Pence Pence Pence Pence
--------------------------------------------------- ----------- ----------- ------ ------
From continuing operations attributable to
the ordinary equity holders
of the company 11.7 12.3 (0.4) 0.2
From discontinued operation 0.1 0.3 (1.3) 0.2
--------------------------------------------------- ----------- ----------- ------ ------
Total basic earnings/(loss) per share attributable
to the ordinary equity holders of the company 11.8 12.5 (1.7) 0.4
--------------------------------------------------- ----------- ----------- ------ ------
10. Goodwill
On acquisition, goodwill acquired in a business combination is
allocated to the cash-generating units which are expected to
benefit from that business combination. These cash-generating units
correspond to the nature of the business, following the separate
divisions Pharmaceuticals and Wholesale. The goodwill has been
allocated to the cash-generating units ("CGU") as follows:
For the year ended
31 December
--------------------- --------------------
GBP'000 2018 2017
--------------------- --------- ---------
CGU: Pharmaceuticals 50,937 50,856
CGU: Wholesale - 557
--------------------- --------- ---------
Total 50,937 51,413
--------------------- --------- ---------
The changes in the carrying value of the goodwill can be
presented as follows for the years 2018 and 2017:
GBP'000 Total
--------------------- ------
At 1 January 2017 9,958
Additions 41,048
Currency translation 406
--------------------- ------
At 31 December 2017 51,413
Disposals (106)
Impairment (456)
Currency translation 86
--------------------- ------
At 31 December 2018 50,937
--------------------- ------
The goodwill balance decreased as a result of the disposal of
Medini nv in 2018 by GBP106k (see note 3) and impairment of
goodwill relating to the non-core Orthopaedics business by
GBP456k.
Goodwill allocated to the Pharmaceuticals CGU includes goodwill
recognised as a result of past business combinations of Esteve,
Equipharma NV, Ecuphar BV, Cardon Pharmaceuticals NV and the
reverse acquisition of Animalcare Group plc in 2017. As of 31
December 2018, no goodwill is allocated to the Wholesale CGU
following the disposal of Medini nv.
The discount rate and growth rate (in perpetuity) used for value
in use calculations are as follows:
2018 2017
Discount rate (pre-tax) 10.5 10.2
Growth rate (in perpetuity) % 2.0 2.0
Cash flow forecasts are prepared using the current operating
budget approved by the Directors, which covers a three-year period
and an appropriate extrapolation of cash flows beyond this. The
cash flow forecasts assume revenue and profit growth in line with
our strategic priorities.
The Group's impairment review is sensitive to a change in
assumptions used, most notably the discount rates and the
perpetuity growth rates.
A 1% increase in discount rates would cause the value in use of
the CGU to reduce by GBP14.0m but would not give rise to an
impairment.
A 1% reduction in perpetuity growth rates would cause the value
in use of the CGU to reduce by GBP12.5m but would not give rise to
an impairment.
The CGU is highly sensitive to any reductions in short-term cash
flows, whether driven by lower sales growth, lower operating
profits or lower cash conversion. A 15% reduction in total annual
cash flows would give rise to an impairment of GBP0.5m in the CGU.
An increase in discount rates of 2.21% or a reduction in perpetuity
growth rates of 2.6% would also give rise to an impairment in the
CGU of GBP48k and GBP235k respectively.
11. Intangible assets
The changes in the carrying value of the intangible assets can
be presented as follows for the years 2018 and 2017:
Patents, Product portfolios
distribution & product
In Process rights development Capitalized
GBP'000 R&D & licenses costs software Total
----------------------- ---------- ------------- ------------------ ----------- --------
Acquisition value
At 1 January 2017 2,839 12,437 16,956 187 32,419
Additions 550 187 1,174 468 2,379
Change due to business
combinations 10,013 4,561 21,041 - 35,615
Disposals - (29) - - (29)
Currency translation 116 510 704 14 1,344
Other - 19 - 48 67
----------------------- ---------- ------------- ------------------ ----------- --------
At 31 December 2017 13,518 17,685 39,875 717 71,795
----------------------- ---------- ------------- ------------------ ----------- --------
Additions 3,525 1,340 670 452 5,987
Change due to business
combinations - (29) (5) - (34)
Currency translation 36 104 128 12 280
Other - 8 - - 8
----------------------- ---------- ------------- ------------------ ----------- --------
At 31 December 2018 17,079 19,108 40,668 1,181 78,036
----------------------- ---------- ------------- ------------------ ----------- --------
Amortization
At 1 January 2017 (467) (2,351) (8,298) (57) (11,173)
Additions (751) (2,523) (2,589) (190) (6,053)
Currency translation (23) (124) (359) (5) (511)
Other - 8 5 (34) (21)
----------------------- ---------- ------------- ------------------ ----------- --------
At 31 December 2017 (1,241) (4,990) (11,241) (286) (17,758)
----------------------- ---------- ------------- ------------------ ----------- --------
Additions (1,423) (2,716) (3,504) (322) (7,965)
Change due to business
combinations - 29 3 - 32
Impairments (852) - - - (852)
Currency translation (10) (64) (76) (6) (156)
Transfers - - - (15) (15)
Other (10) 20 2 - 12
----------------------- ---------- ------------- ------------------ ----------- --------
At 31 December 2018 (3,536) (7,721) (14,816) (629) (26,702)
----------------------- ---------- ------------- ------------------ ----------- --------
Net carrying value
At 31 December 2018 13,543 11,387 25,852 552 51,334
At 31 December 2017 12,277 12,695 28,634 431 54,037
----------------------- ---------- ------------- ------------------ ----------- --------
12. Borrowings
The loans and borrowings include the following:
For the year ended
31 December
------------------------------ --------------------
Interest
GBP'000 rate Maturity 2018 2017
------------------------------ -------- -------- --------- ---------
Other loans 1.56% 22 51
Euribor
Revolving credit facilities +1.50% March 22 25,513 26,768
Euribor
Roll over investment facility +1.50% March 22 2,063 2,676
Euribor
Acquisition loan +1.75% March 22 4,025 3,992
Total loans and borrowings 31,623 33,487
------------------------------ -------- -------- --------- ---------
of which non -current 30,975 32,854
current 648 633
------------------------------ -------- -------- --------- ---------
Revolving credit facilities and roll over investment
facilities
In mid-2016, the Group refinanced all of its outstanding
investment loans with different banks. Financing arrangements were
entered into with four Belgian banks. These financing arrangements
have been split equally amongst these four banks. The agreements
consist of:
EUR41.5m revolving credit facilities
EUR10m available acquisition financing
EUR4.08m investment loans
The loans have a variable, EURIBOR based interest rate,
increased with a margin of 1.5% or 1.75%. The revolving credit
facilities and the acquisition financing have a bullet maturity in
March 2022. The investment loans are repaid in 23 monthly
instalments.
13. Deferred income and accrued charges
Deferred income and accrued charges consist of the
following:
For the year ended
31 December
-------------------------------------- --------------------
GBP'000 2018 2017
-------------------------------------- --------- ---------
Accrued charges 2,133 1,868
Deferred income - due within one year 190 219
Other 2 29
-------------------------------------- --------- ---------
Total due within one year 2,325 2,116
-------------------------------------- --------- ---------
Deferred income - Due after one year 617 780
-------------------------------------- --------- ---------
Accrued charges mainly relate to accrued product development
expenses of GBP1,188k (2017: GBP757k) and several accrued charges
relating to commissions and bonuses in Ecuphar Veterinaria for an
amount of GBP255k (2017: GBP333k) and GBP181k for Belphar.
Deferred income are contract liabilities that arise from certain
services sold by the Group's subsidiary Animalcare Ltd. In return
for a single upfront payment, Animalcare Ltd commits to a fixed
term contract to provide certain database, pet reunification and
other support services to customers. There is no contractual
restriction on the amount of times the customer makes use of the
services. At the commencement of the contract, it is not possible
to determine how many times the customer will make use of the
services, nor does historical evidence provide indications of any
future pattern of use. As such, income is recognised evenly over
the term of the contract, currently between 8 and 14 years.
Movements in the Group's deferred income liabilities during the
current year are as follows:
For the year ended
31 December
------------------------------------------------- --------------------
GBP'000 2018 2017
------------------------------------------------- --------- ---------
Balance at the beginning of the year 999 -
Acquired through business combinations - 925
Income deferred to following periods 139 181
Release of income deferred from previous periods (331) (107)
------------------------------------------------- --------- ---------
Balance at the end of the year 807 999
------------------------------------------------- --------- ---------
14. Equity
Share capital
For the year ended
31 December
--------------------------------------------------- ----------------------
Number of shares 2018 2017
--------------------------------------------------- ---------- ----------
Allotted, called up and fully paid Ordinary Shares
of 20p each 60,057,161 59,913,900
--------------------------------------------------- ---------- ----------
For the year ended
31 December
--------------------------------------------------- --------------------
GBP'000 2018 2017
--------------------------------------------------- --------- ---------
Allotted, called up and fully paid Ordinary Shares
of 20p each 12,012 11,983
--------------------------------------------------- --------- ---------
The following share transactions have taken place during the
year ended 31st December 2018:
For the year ended
31 December
--------------------------- --------------------
GBP'000, except share data 2018 2017
--------------------------- ------------ ------
At 1 January 2018 59,913,900 11,983
Exercise of share options 143,261 29
--------------------------- ------------ ------
At 31 December 2018 60,057,161 12,012
--------------------------- ------------ ------
On 13th July 2017, the Group completed the reverse acquisition
of Animalcare Group plc. In aggregate, 37,322,894 new Ordinary
Shares were allotted and issued, comprising 8,571,428 new placing
shares and 28,751,466 consideration shares.
During the year a total of 143,261 shares were issued in
relation to the grant of options over the Company's share by
Animalcare Ltd under the Animalcare Group plc Executive Share
Option Scheme and the Save As You Earn (SAYE) Share Option
Scheme.
Dividends
For the year ended
31 December
----------------------------------------------------- --------------------
GBP'000, except share data 2018 2017
----------------------------------------------------- --------- ---------
Ordinary interim dividend for the period ended 30th
June 2017 of 4.7p per share - 2,816
Ordinary final dividend paid for the year ended 31st
December 2017 of 2.0p per share 1,200 -
Ordinary interim dividend paid for the period ended
30th June 2018 of 2.0 per share 1,201 -
----------------------------------------------------- --------- ---------
2,401 2,816
----------------------------------------------------- --------- ---------
The proposed final dividend of 2.4 pence per share is subject to
approval of shareholders at the Annual General Meeting and has not
been included as a liability as at 31st December 2018, in
accordance with IAS 10 "Events After the Balance Sheet Date".
Non-controlling interest
The non-controlling interest is GBPnil at 31st December 2018
(2017: GBP2k). The decrease to GBPnil during 2018 is due to the
sale of the Wholesaling business.
15. Annual Report
This Preliminary financial information is not being sent to
Shareholders.
A further announcement will be made when the Annual Report and
Accounts for the year ended 31(st) December will be made available
on the Company's website and copies sent to shareholders.
Further copies will be available to download on the Company's
website at: www.animalcaregroup.co.uk and will also be available
from the Company's registered office address: 10 Great North Way,
York Business Park, Nether Poppleton, York, YO26 6RB
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FR CKKDQPBKKNQN
(END) Dow Jones Newswires
April 30, 2019 02:01 ET (06:01 GMT)
Animalcare (AQSE:ANCR.GB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Animalcare (AQSE:ANCR.GB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
